Sodium-glucose Cotransporter Type 2 Inhibitors for Acute Cardiorenal Syndrome Prevention
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
The effect of sodium-glucose cotransporter type 2 inhibitors (SGLT2i) on the parameters of
renal function in acute decompensation of chronic heart failure (CHF) compared to standard
therapy will be analyzed. Based on the dynamics of the clinical condition, the duration of
hospitalization, and blood biochemical parameters (creatinine, urea, uric acid, potassium,
sodium, N-terminal pro-brain natriuretic peptide NT-proBNP) conclusions will be drawn about
the possibility of using SGLT2i in this group of patients.
Phase:
Phase 4
Details
Lead Sponsor:
I.M. Sechenov First Moscow State Medical University